LBRX LBRX Clinical Trial — Direct Research And Development Expenses

Similar metrics at other companies

MPLTClinical Trial — Research And Development Expense

$24.82M+1,180%

GERNResearch and clinical expenses — R&D

$13M-5.1%

TNGXDiscovery Direct Program Expenses-RD — Research And Development Expense

$1.87M-60.0%

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

INBXReportable Segment — Research And Development Expense, Clinical Trials

$9.18M-30.8%

Questions, answered.

What is LBRX's clinical trial — direct research and development expenses?

LBRX (LBRX) reported clinical trial — direct research and development expenses of $1.18M in Q4 2025.

How has LBRX's clinical trial — direct research and development expenses changed year-over-year?

LBRX's clinical trial — direct research and development expenses decreased by 88.8% year-over-year, from $10.59M to $1.18M.

What does clinical trial — direct research and development expenses mean?

This metric represents the direct costs incurred specifically for conducting clinical trials and related research activities for a particular drug candidate or therapeutic program. It encompasses expenses such as patient recruitment, site management, clinical monitoring, and data analysis required to advance a product through regulatory development phases. Monitoring these costs provides insight into the capital intensity and progress of a company's clinical-stage pipeline.